These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 6410637

  • 1. Observations on PUVA treatment of psoriasis and on 5-S-cysteinyldopa after exposure to UV light.
    Tegner E.
    Acta Derm Venereol Suppl (Stockh); 1983; 107():1-68. PubMed ID: 6410637
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 5-S-Cysteinyldopa and dopa in serum during treatment with 8-methoxypsoralen and UVA light.
    Hansson C, Rorsman H, Rosengren E, Tegner E.
    Acta Derm Venereol; 1981; 61(3):251-5. PubMed ID: 6167110
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term risks of psoralen and UV-A therapy for psoriasis.
    Farber EM, Abel EA, Cox AJ.
    Arch Dermatol; 1983 May; 119(5):426-31. PubMed ID: 6342539
    [Abstract] [Full Text] [Related]

  • 6. Biochemical observations in UV-induced pigmentation.
    Rorsman H, Tegner E.
    Photodermatol; 1988 Feb; 5(1):30-8. PubMed ID: 3281148
    [Abstract] [Full Text] [Related]

  • 7. Tissue anoxia prevents inflammation and pigmentation caused by UVA but not by UVB or PUVA.
    Tegner E.
    Photodermatol; 1984 Dec; 1(6):311-2. PubMed ID: 6533624
    [No Abstract] [Full Text] [Related]

  • 8. Lenticular psoralen photoproducts and cataracts of a PUVA-treated psoriatic patient.
    Woo TY, Wong RC, Wong JM, Anderson TF, Lerman S.
    Arch Dermatol; 1985 Oct; 121(10):1307-8. PubMed ID: 4037825
    [Abstract] [Full Text] [Related]

  • 9. Urinary excretion of 5-S-cysteinyldopa is enhanced by PUVA and is independent of skin type.
    Tardy J, Barrois JP, Bendelac A, Leonard F, Triller R, Jardillier JC, Kalis B.
    Photodermatol; 1987 Aug; 4(4):205-8. PubMed ID: 3124084
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risk of skin tumors in psoralen- and ultraviolet A-treated patients.
    Henseler T, Christophers E.
    Natl Cancer Inst Monogr; 1984 Dec; 66():217-9. PubMed ID: 6531033
    [Abstract] [Full Text] [Related]

  • 12. Psoralens in photochemotherapy of skin diseases.
    Pathak MA, Parrish JA, Fitzpatrick TB.
    Farmaco Sci; 1981 Jul; 36(7):479-91. PubMed ID: 7274436
    [No Abstract] [Full Text] [Related]

  • 13. [Effect of drugs and ultraviolet rays on the development of pemphigoid].
    Lutowiecka-Wranicz A, Sysa-Jedrzejowska A, Skwarczyńska-Banyś E.
    Przegl Dermatol; 1980 Jul; 67(5):641-6. PubMed ID: 7005972
    [No Abstract] [Full Text] [Related]

  • 14. The pigmentary response to photochemotherapy.
    Zaynoun S, Konrad K, Gschnait F, Wolff K.
    Acta Derm Venereol; 1977 Jul; 57(5):431-40. PubMed ID: 73310
    [Abstract] [Full Text] [Related]

  • 15. [Effect of PUVA and SUP therapy on nevocellular nevi (author's transl)].
    Pullmann H, Theunissen A, Galosi A, Steigleder GK.
    Z Hautkr; 1981 Nov 01; 56(21):1412-7. PubMed ID: 7314762
    [Abstract] [Full Text] [Related]

  • 16. Plasma 5-S-cysteinyldopa as an index of melanogenesis.
    Nimmo JE, Gawkrodger DJ, O'Docherty CS, Going SM, Percy-Robb IW, Hunter JA.
    Br J Dermatol; 1988 Apr 01; 118(4):487-95. PubMed ID: 3132198
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.